Karyopharm Therapeutics (KPTI) AI Stock Analysis

• Market Cap: $59.66M
• Dividend Yield: N/A
• Average Volume (3M): 172.35K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.44
• Revenue Growth: -5.77%
• EPS Growth: -22.78%
• Country: US
• Employees: 279
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -4.32
• Shares Outstanding: 8,671,278
• 10 Day Avg. Volume: 126,920
• 30 Day Avg. Volume: 172,347
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 2.95
• Enterprise Value/Revenue: 1.28
• Enterprise Value/Gross Profit: 1.33
• Enterprise Value/Ebitda: -2.29
• 1Y Price Target: $18.25
• Price Target Upside: 174.02% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5

• Rating: 54 Neutral
• Price Target: $7.50 ▲(12.61% Upside)

Karyopharm Therapeutics' overall stock score is primarily impacted by its significant financial challenges, including declining revenues, persistent losses, and high leverage. While technical indicators show positive momentum, the negative P/E ratio and lack of dividend yield detract from its attractiveness. The earnings call highlighted some positive developments in clinical trials and cost optimization, but financial constraints and debt maturity remain concerns.

Positive Factors

Product Revenue Growth

The increase in XPOVIO revenue indicates strong demand and market penetration, supporting long-term revenue growth and sustainability.

Global Expansion

Global expansion enhances market reach and diversifies revenue streams, reducing dependency on any single market and supporting long-term growth.

Cost Optimization

Cost optimization efforts improve operational efficiency, potentially leading to better profitability and financial health over time.

Negative Factors

Financial Constraints

Financial constraints and upcoming debt maturity pose risks to liquidity and may limit the company's ability to invest in growth opportunities.

Declining Total Revenue

A decline in total revenue indicates potential challenges in sustaining growth and could impact long-term financial stability.

Net Loss

Persistent net losses highlight ongoing operational inefficiencies and could strain resources, affecting the company's ability to fund future growth.

Karyopharm Therapeutics Business Overview & Revenue Model

Company Description

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

How the Company Makes Money

Karyopharm Therapeutics generates revenue primarily through the sale of its approved drug Xpovio, which is marketed for the treatment of multiple myeloma and certain lymphomas. The company also earns revenue from collaborations and partnerships with other pharmaceutical and biotechnology companies, which may include upfront payments, milestone payments, and royalties on future sales. Additionally, Karyopharm may receive funding from government grants or research initiatives focused on cancer therapies. The company's ability to successfully navigate clinical trials and gain further regulatory approvals for its pipeline products will be pivotal in expanding its revenue streams.

Karyopharm Therapeutics Financial Statement Overview

Summary

Karyopharm Therapeutics faces significant financial challenges, including declining revenues, persistent losses, high leverage, and negative equity. Cash flow analysis shows insufficient operational cash generation, leading to reliance on external financing.

Income Statement

Karyopharm Therapeutics has experienced declining revenue over recent years, with a negative revenue growth rate of -0.55% from 2023 to 2024. The company also faces significant profitability challenges, as indicated by negative net profit margins and EBIT margins. Despite a relatively high gross profit margin of 95.87% in 2024, the persistent net losses highlight ongoing operational inefficiencies.

Balance Sheet

The balance sheet shows a concerning financial position with negative stockholders' equity, indicating liabilities exceed assets. The debt-to-equity ratio cannot be calculated due to negative equity, but the high total debt relative to assets suggests significant leverage. The equity ratio is negative, further emphasizing the financial instability and potential solvency risks.

Cash Flow

Karyopharm Therapeutics has negative free cash flow, which deteriorated by 37.66% from 2023 to 2024. The operating cash flow to net income ratio is negative, reflecting cash flow challenges. Although there was a positive financing cash flow, it is insufficient to offset the negative operating cash flow, indicating reliance on external financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	137.27M	145.24M	146.03M	157.07M	209.82M	108.08M
Gross Profit	132.29M	139.23M	141.09M	151.86M	206.42M	105.38M
EBITDA	-76.92M	-38.60M	-118.42M	-139.31M	-96.98M	-167.85M
Net Income	-123.57M	-76.42M	-143.10M	-165.29M	-124.09M	-196.27M
Balance Sheet
Total Assets	104.88M	164.42M	240.44M	358.17M	305.31M	313.05M
Cash, Cash Equivalents and Short-Term Investments	38.73M	108.71M	191.44M	277.97M	228.62M	249.24M
Total Debt	94.80M	194.52M	177.02M	179.07M	180.58M	131.13M
Total Liabilities	343.81M	350.44M	376.64M	374.83M	384.98M	262.50M
Stockholders Equity	-238.93M	-186.02M	-136.21M	-16.66M	-79.67M	50.55M
Cash Flow
Free Cash Flow	-102.89M	-127.63M	-92.72M	-149.67M	-112.83M	-160.38M
Operating Cash Flow	-102.94M	-127.49M	-92.72M	-149.55M	-107.12M	-160.23M
Investing Cash Flow	55.84M	95.47M	7.94M	-104.26M	141.84M	-53.69M
Financing Cash Flow	1.04M	41.65M	1.12M	193.74M	73.65M	172.08M

Karyopharm Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.66
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KPTI, the sentiment is Positive. The current price of 6.66 is above the 20-day moving average (MA) of 6.52, above the 50-day MA of 5.50, and above the 200-day MA of 6.58, indicating a bullish trend. The MACD of 0.21 indicates Positive momentum. The RSI at 54.51 is Neutral, neither overbought nor oversold. The STOCH value of 65.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KPTI.

Karyopharm Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KPTI	54 Neutral	$59.66M	―	41.08%	―	-5.77%	-22.78%
CNTB	49 Neutral	―	-5.97	―	―	―	―
HOWL	48 Neutral	94.89M	-1.23	-96.08%	―	-100.00%	-22.09%
XFOR	44 Neutral	80.14M	-0.23	―	―	5721.31%	-671.01%
PEPG	40 Underperform	87.25M	-1.98	―	―	―	10.04%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Karyopharm Therapeutics Corporate Events

Karyopharm Therapeutics Board Member Resigns Amid Career Shift

On September 5, 2025, Mansoor Raza Mirza, M.D., a member of the Board of Directors of Karyopharm Therapeutics Inc., announced his resignation effective September 8, 2025, due to competing professional demands. Dr. Mirza’s resignation is not related to any disagreements with the company, and he is also stepping down from his role as Chief Oncologist at Copenhagen University National Medical Center to pursue a new executive role in the industry. Consequently, the consulting agreement between Karyopharm and Mirza Consulting was terminated as of September 8, 2025.

The most recent analyst rating on (KPTI) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Karyopharm Therapeutics stock, see the KPTI Stock Forecast page.